A full manuscript has been submitted for journal peer review and is anticipated to be published in rheumatology journals in early 2023. The summary of the guideline recommendations can be viewed in full on the ACR website: https://tinyurl.com/32vbw225.
Related Articles
Build Up Bone
Current management of osteoporosis
Osteoporosis Experts Discuss Bisphosphonate Holidays
ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…
Reading Rheum: Which Bone Agent Is Best in High-risk Osteoporosis?
Handpicked Reviews of Contemporary Literature
Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia
Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common subtype of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….